After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor-Positive Metastatic Breast Cancer

By afschroeder • June 21, 2025

Teysir J, Lloyd MR, Alkassis S, Callahan RD, Fairley R, Wander SA, Bardia A, Jhaveri KL. After a CDK4/6 Inhibitor: State of the Art in Hormone Receptor-Positive Metastatic Breast Cancer. Am Soc Clin Oncol Educ Book. 2025 Jun;45(3):e473372. doi: 10.1200/EDBK-25-473372. Epub 2025 Jun 20. PMID: 40540707.

Tags: Hematology/Oncology, Publications

Single-agent mosunetuzumab in older or unfit patients with previously untreated DLBCL: results of a phase 1/2 trial

Olszewski AJ, Avigdor A, Babu S, Levi I, Eradat H, Abadi U, Holmes H, McKinney MS, Woszczyk D, Giannopoulos K, Jurczak W, Jing J, Li[...]

Personalizing cancer care for older adults

Ji J, Sedrak MS. Personalizing cancer care for older adults. J Gerontol A Biol Sci Med Sci. 2026 Jun 6;81(7):glag126. doi: 10.1093/gerona/glag126. PMID: 42329168; PMCID:[...]

Receptor discordance between primary tumors and nodal metastases and correlation with the 21-gene recurrence score in early-stage, estrogen receptor-positive, node-positive breast cancer

Zheng S, Sullivan P, Vadehra K, Kim J, Levee A, Callahan R, Teshome M, Tseng CH, Bardia A, Kapoor NS. Receptor discordance between primary tumors[...]